SG Americas Securities LLC Sells 37,638 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

SG Americas Securities LLC cut its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 85.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,554 shares of the biotechnology company’s stock after selling 37,638 shares during the period. SG Americas Securities LLC’s holdings in ADMA Biologics were worth $112,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. State Street Corp increased its position in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after acquiring an additional 4,945,063 shares during the period. Perpetual Ltd bought a new position in ADMA Biologics in the fourth quarter worth approximately $62,300,000. Lord Abbett & CO. LLC bought a new position in ADMA Biologics in the third quarter worth approximately $61,858,000. Principal Financial Group Inc. increased its holdings in ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after purchasing an additional 1,059,394 shares during the period. Finally, First Turn Management LLC bought a new stake in ADMA Biologics during the 3rd quarter valued at $13,293,000. 75.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ADMA has been the topic of a number of recent research reports. HC Wainwright increased their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Stock Down 0.3 %

ADMA Biologics stock opened at $15.84 on Thursday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a market cap of $3.74 billion, a P/E ratio of 56.57 and a beta of 0.75. The business has a fifty day moving average of $17.50 and a two-hundred day moving average of $17.77. ADMA Biologics, Inc. has a twelve month low of $5.02 and a twelve month high of $23.64.

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.